港股异动 绿叶制药(02186)涨近3% 米美欣®等五款新品获纳入国家医保药品目录或商保创新药目录

Core Viewpoint - Green Leaf Pharmaceutical (02186) has seen a nearly 3% increase in stock price, attributed to the successful inclusion of five new products in the National Medical Insurance Catalog for 2025 and the Commercial Health Insurance Innovative Drug Catalog for 2025 [1]. Group 1: Stock Performance - Green Leaf Pharmaceutical's stock rose by 2.66%, reaching HKD 3.09, with a trading volume of HKD 8.3751 million [1]. Group 2: Product Inclusion - Five new products from Green Leaf Pharmaceutical have been successfully included in the National Medical Insurance Catalog and the Commercial Health Insurance Innovative Drug Catalog for 2025 [1]. - The new products include: - MiMeiXin® (Oxycodone Naloxone Extended-Release Tablets) and RuiBaiLai® (Paliperidone Palmitate Injection (II)) are newly included in the National Medical Insurance Catalog [1]. - ZanBiJia® (Injectable Lurbinectedin) has been successfully included in the Commercial Health Insurance Innovative Drug Catalog [1]. - BaiTuoWei® (Injectable Goserelin Microspheres) and RuiKeTuo® (Injectable Risperidone Microspheres (II)) have successfully renewed their inclusion in the National Medical Insurance Catalog [1].